Dupont Capital Management Corp reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,837 shares of the medical research company’s stock after selling 1,229 shares during the quarter. Dupont Capital Management Corp’s holdings in Thermo Fisher Scientific were worth $7,039,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the stock. Pitcairn Co. lifted its holdings in shares of Thermo Fisher Scientific by 1.3% during the second quarter. Pitcairn Co. now owns 16,871 shares of the medical research company’s stock valued at $3,495,000 after acquiring an additional 215 shares during the period. Hall Capital Management Co. Inc. raised its holdings in shares of Thermo Fisher Scientific by 6.2% in the third quarter. Hall Capital Management Co. Inc. now owns 3,780 shares of the medical research company’s stock valued at $923,000 after buying an additional 220 shares during the last quarter. Nvwm LLC raised its holdings in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Nvwm LLC now owns 4,231 shares of the medical research company’s stock valued at $877,000 after buying an additional 242 shares during the last quarter. Tiedemann Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 19.4% in the second quarter. Tiedemann Advisors LLC now owns 1,518 shares of the medical research company’s stock valued at $315,000 after buying an additional 247 shares during the last quarter. Finally, Chesapeake Wealth Management raised its holdings in shares of Thermo Fisher Scientific by 6.0% in the second quarter. Chesapeake Wealth Management now owns 4,393 shares of the medical research company’s stock valued at $910,000 after buying an additional 249 shares during the last quarter. 85.22% of the stock is owned by hedge funds and other institutional investors.
Thermo Fisher Scientific stock opened at $243.45 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.84 and a quick ratio of 1.27. Thermo Fisher Scientific Inc. has a 12-month low of $181.51 and a 12-month high of $249.95. The stock has a market capitalization of $95.91 billion, a P/E ratio of 25.65, a price-to-earnings-growth ratio of 1.73 and a beta of 1.08.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 24th. The medical research company reported $2.62 EPS for the quarter, topping the Zacks’ consensus estimate of $2.55 by $0.07. The firm had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.70 billion. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The company’s revenue was up 15.7% on a year-over-year basis. During the same period last year, the company earned $2.31 earnings per share. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 11.04 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 15th. Investors of record on Monday, December 17th will be given a $0.17 dividend. The ex-dividend date is Friday, December 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 7.17%.
Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Friday, September 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2.1% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.
TMO has been the subject of a number of research analyst reports. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $230.00 to $233.00 and gave the company an “overweight” rating in a report on Friday, July 13th. Zacks Investment Research cut Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a report on Tuesday, July 24th. ValuEngine raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, July 24th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $300.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 26th. Finally, Leerink Swann lifted their price target on Thermo Fisher Scientific from $239.00 to $255.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $261.45.
In related news, CEO Marc N. Casper sold 125,520 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $247.50, for a total value of $31,066,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.49% of the stock is owned by company insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
See Also: How to Invest in Marijuana Stocks
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.